Oscar Health (OSCR) has opened 2026 with a sharp swing into profitability in its latest quarter, posting Q1 revenue of about US$4.6 billion alongside basic EPS of US$2.28 on net income of roughly US$679 million, versus Q1 2025 revenue of about US$3.0 billion and EPS of US$1.10. Over the trailing twelve months to Q1 2026, revenue has moved from roughly US$9.2 billion to about US$13.3 billion, while EPS on the same basis shifted from US$0.11 to a small loss of US$0.14, highlighting how the strong quarterly print contrasts with a still loss making year. For investors, this mix of robust top line and quarterly profitability against a thin trailing margin profile puts the focus squarely on how durable these margin gains really are.

See our full analysis for Oscar Health.

With the headline numbers set, the next step is to see how this latest earnings snapshot lines up against the prevailing narratives around Oscar Health's growth potential, risk profile, and path to sustainable profitability.

Sharp swing from recent losses

• Q1 2026 net income of about US$679 million and basic EPS of US$2.28 follow three straight quarters of losses in 2025, where EPS ranged from a US$0.53 loss to a US$1.24 loss.
• Bulls argue this kind of profitability jump fits a story of margin expansion and better cost control. However, the last twelve months still show a small net loss of about US$39 million and a basic EPS loss of US$0.14, so:
  • Consensus style bullish views point to multi year loss reduction and forecast earnings growth of 67.43% per year, but the recent run of loss making quarters in 2025 shows that profitability has not been consistently in place.
  • The strong Q1 result heavily supports the bullish idea that cost initiatives can work, while the loss on a trailing basis keeps the question of how repeatable this quarter is firmly on the table.

Bulls who see Q1 as a turning point may want the full story on how that view lines up with longer term expectations and scenario work for Oscar Health, and how those assumptions compare to alternative bullish cases for other insurers, before leaning on one quarter too heavily. 🐂 Oscar Health Bull Case

LTM loss vs 13.7% growth outlook

• On a trailing twelve month basis to Q1 2026, Oscar generated about US$13.3b of revenue but still reported a net loss of roughly US$39 million, while forecasts cite 13.7% annual revenue growth and earnings growth of 67.43% per year.
• Bears highlight that reliance on ACA individual markets and higher medical costs could keep pressure on profitability. The trailing loss plus the forecasted 13.7% growth rate create some tension with those concerns:
  • Critics point to ongoing high medical loss ratios and policy risk as threats to future earnings, and the fact that the company remains loss making over the last twelve months gives that cautious view clear numerical backing.
  • At the same time, the revenue base has scaled from about US$9.2b to roughly US$13.3b over recent trailing periods, which is consistent with the growth side of the story that cautious investors acknowledge even as they focus on the earnings drag.

Skeptics who focus on medical cost pressures may find it useful to see how this cautious angle frames Q1 alongside scenarios where growth continues but margins stay under pressure, and how that stacks up against other insurers facing similar issues. 🐻 Oscar Health Bear Case

P/S of 0.4x versus industry 1.1x

• Oscar is trading on a P/S of 0.4x, compared with a peer average of 0.6x and a US Insurance industry average of 1.1x, while the current share price is US$19.84 and the only price target figure you can benchmark against here is US$17.10.
• Consensus narrative suggests that relatively low sales multiples and growth projections can make the stock look inexpensive. However, the unprofitable trailing twelve month profile and recent shareholder dilution are key counterpoints:
  • Supporters of the consensus view point to forecast revenue growth of 13.7% per year and the below industry P/S of 0.4x as signs that the stock is pricing in more modest expectations than its growth profile might imply.
  • On the other hand, shareholders saw dilution over the past year and the latest twelve month net loss of about US$39 million shows that, despite Q1, the business is not yet reporting steady profits, which helps explain why the P/S multiple sits below broader insurance peers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Oscar Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, sentiment here is clearly mixed. It makes sense to look at the full data set yourself and move quickly to shape your own view by weighing the 2 key rewards and 1 important warning sign

Explore Alternatives

Despite a strong Q1, Oscar Health still reports a trailing twelve month net loss, inconsistent profitability, shareholder dilution, and a P/S below broader insurance peers.

If you are uneasy about that mix of losses and dilution, it is worth comparing against companies in the 74 resilient stocks with low risk scores that focus on resilience and steadier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.